Phase 4
Completed N=70
Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Source: ClinicalTrials.gov NCT00836641 ↗Enrolled (actual)
70
Serious AEs
—
Results posted
Sep 2013
Primary outcomePrimary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Summary
Asthma is a major health problem in preschool children. Infections by pneumococci a the most frequent cause of airway infections, which tend to cause worsening of asthma. Vaccination against pneumococci is recommended by scientific boards and the medical community, in order to reduce the burden of disease. Data on the immunogenicity and safety of pneumococcal immunization in preschool asthmatics are scarce.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Immunogenicity of Pneumococcal Vaccination |
0.05; 0.05 | — |
| SECONDARY Number of Vaccinees With Adverse Events |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- asthma classified according to the Global Initiative on Asthma (GINA) °1-2
Exclusion Criteria
- antecedent pneumococcal immunization
Data sourced from ClinicalTrials.gov (NCT00836641). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.